|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ƥ����Ī˾ |
|
�������Ƽ� |
|
��֢��Ƥ���� |
| ��������������� | |
|
�߽��� |
|
��־ǿ |
| PubMed | |
|
Article by |
|
Article by |
�µ��������Ƽ�����ƥ����Ī˾
�߽���, ��־ǿ
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
ƥ����Ī˾��һ���µ��������Ƽ�,����ϸ�����������͵�����macrophilin��Ϻ����ƸƵ�����ø�Ļ��ԡ���������Tϸ����ͷʴ�ϸ���ͷ�ϸ������,����Ч������֢��Ƥ�����������ص������ƥ����Ī˾,���Խ��������������������
[2] Grassberger M,Baumruker T,Enz A,et al.A novel anti-inflammatory drug,SDZ ASM 981,for the treatment of skin diseases:in vitro pharma-cology.Br J Dermatol,1999,141 (2):264-273.
[3] Peterson LB,Cryan JG,Rosa R,et al.A tacrolimus-related immtmosup-pressant with biochemical properties distinct from those of tacrolimus.Transplantation,1998,65(1):10-18.
[4] Van Leent EJ,Graber M,Thurston M,et al.Effectiveness of the as-comycin macrolactam SDZ ASM 981 in the topical treatment of atopic der-matitis.Arch Dermatol,1998,134(7):805-809.
[5] Neckermann G,Bavandi A,Meingassner JG.Atopic dermatitis-like symp-toms in hypomagnesaemic hairless rats are prevented and inhibited by sys-temic or topical SDZ ASM 981.Br J Dermatol,2000,142(4):669-679.
[6] Meingassner JG,Grassberger M,Fahrngruber H,et al.A novel anti-in-flammatory drug,SDZ ASM 981,for the topical and oral treatment of skin diseases:in vivo pharmacology.Br J Dermatol,1997,137(4):568-576.
[7] Harper J,Green A,Scott G,et al.First experience of topical SDZ ASM 981 in children with atopic dermatitis.Br J Dertnatol,2001,144(4):781-787.
[8] Queille-Roussel C,Paul C,Duteil L,et al.The new topical ascomycin derivative SDZ ASM 981 does not induce akin atrophy when applied to normal skin for 4 weeks:a randomized,double-blind controlled study.Br J Dermatol,2001,144(3):507-513.
[9] Mrowietz U,Graeber M,Brautigam M,et al.The novel ascomycin deriva-tive SDZ ASM 981 is effective for psoriasis when used topically under oc-clusion.Br J Dermatol,1998,139:992-996.
[10] Rappersberger K,Komar M,Ebelin ME,et al.Clinical experience with oral SDZ ASM 981 in psoriasis.J Eur Acad Dermatol Venereol,2000,14(Suppl 1):255.
[11] Rappersberger K,Meingassner JG,FiaUa R,et al.Cleating of psoriasis by a novel immunosuppressive macrolide.J Invest Dermatol,1996,106(4):701-710.
[12] Luger T,Van Leent EJ,Graeber M,et al.SDZ ASM 981:an emerging safe and effective treatment for atopie dermatitis.Br J Dermatol,2001,144(4):788-794.
[13] Queille-Roussel C,Graeber M,Thurston M,et al.SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicit-ed by allergen challenge.Contact Dermatitis,2000,42(6):349-350.
[14] eherill R,Tofte S,MaeNaul R,et al.SDZ ASM 981 1%cream is effective in the treatment of chronic irritant hand dermatitis.J Eur Aead Derm Venereol,2000,14(Suppl 1):128.
[15] Mollison KW,Fey TA,Krause RA,et al.Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosup-pressant nephrotoxicity with a novel single-dase rat cisplatin potentiation assay.J Phannacol Exp Ther,1997,283(3):1509-1519.
[16] Dtmont FJ,Koprak S,Staruch MJ,et al.A tacrolimus-related immano-suppressant with reduced toxicity.Transplantatien,1998,65 (1):18-26.
[17] Mollison KW,Fey TA,Krause RA,et al.Nephrotoxicity studies of the im-munesuppressants tacrolimmus (FKS06) and ascomycin in rat models.Tox-icology,1998,125:169-181.
[18] Mollison KW,Fey TA,Gauvin DM,et al.A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treat-ment of inflammatory skin diseases.J Invest Dermatol,1999,112(5):729-738.